"Executive Summary:          Langerhans cell histiocytosis (LCH) treatment has seen significant advancements in recent years, particularly in targeted therapies and immunotherapies. The introduction of targeted agents such as vemurafenib and dabrafenib, which target the BRAF mutation commonly found in LCH, has shown promising results in treating refractory cases....